$IKT News

Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatment Of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

Inhibikase Therapeutics Files SEC Prospectus To Raise Up To $185M Through Existing ATM Program

Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company

Reported Earlier, Inhibikase Therapeutics Prices $100M Offering Of 46,091,739 Common Shares At $1.45 And 22,873,779 Pre Funded Warrants At $1.449

Reported Earlier, Inhibikase Therapeutics Prices $100M Offering Of 46,091,739 Common Shares At $1.45 And 22,873,779 Pre Funded Warrants At $1.449

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension